{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:52:26Z","timestamp":1761576746732,"version":"build-2065373602"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"USA National Cancer Institute","award":["R01CA256285"],"award-info":[{"award-number":["R01CA256285"]}]},{"name":"Dallas Swing Fund and Broyhill Family Fund","award":["To Brain Tumor Center of Excellence"],"award-info":[{"award-number":["To Brain Tumor Center of Excellence"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02100-y","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:19:09Z","timestamp":1761571149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate"],"prefix":"10.1186","volume":"27","author":[{"given":"Waldemar","family":"Debinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlin N.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rossmeisl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan T.","family":"Mott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kounosuke","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Herpai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2100_CR1","unstructured":"American Cancer Society. The breast cancer facts & figures 2024\u20132025. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/breast-cancer-facts-figures.html."},{"key":"2100_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2016.36","volume":"2","author":"F Pareja","year":"2016","unstructured":"Pareja F, Geyer FC, Marchi\u00f2 C, Burke KA, Weigelt B, Reis-Filho JS. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer. 2016;2: 16036.","journal-title":"NPJ Breast Cancer"},{"issue":"11","key":"2100_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334.","journal-title":"Clin Cancer Res"},{"key":"2100_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:619\u201326.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"2100_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u201326.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2100_CR7","first-page":"40","volume":"19","author":"P Exman","year":"2021","unstructured":"Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021;19(1):40\u201350.","journal-title":"Clin Adv Hematol Oncol"},{"key":"2100_CR8","first-page":"255","volume":"9","author":"W Debinski","year":"1998","unstructured":"Debinski W. An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Crit Rev Oncog. 1998;9:255\u201368.","journal-title":"Crit Rev Oncog"},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/BF03401786","volume":"6","author":"W Debinski","year":"2000","unstructured":"Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer\/testis antigen. Mol Med. 2000;6:440\u20139.","journal-title":"Mol Med"},{"issue":"5","key":"2100_CR10","first-page":"188802","volume":"1877","author":"M Ja\u00e9n","year":"2022","unstructured":"Ja\u00e9n M, Mart\u00edn-Regalado \u00c1, Bartolom\u00e9 RA, Robles J, Casal JI. Interleukin 13 receptor alpha 2 (IL13R\u03b12): expression, signaling pathways and therapeutic applications in cancer. Biochim Biophys Acta (BBA). 2022;1877(5):188802.","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"2100_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1078-0432.CCR-07-1990","volume":"14","author":"J Wykosky","year":"2008","unstructured":"Wykosky J, Gibo DM, Stanton C, Debinski W. IL-13 receptor alpha-2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res. 2008;14:199\u2013208.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2100_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1541-7786.MCR-05-0056","volume":"3","author":"J Wykosky","year":"2005","unstructured":"Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005;3(10):541\u201351.","journal-title":"Mol Cancer Res"},{"key":"2100_CR13","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1038\/onc.2008.328","volume":"27","author":"J Wykosky","year":"2008","unstructured":"Wykosky J, Palma E, Gibo DM, Ringler S, Turner CP, Debinski W. Soluble monomeric ephrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene. 2008;27:7260\u201373.","journal-title":"Oncogene"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1158\/1535-7163.MCT-07-0200","volume":"6","author":"J Wykosky","year":"2007","unstructured":"Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor-expressing tumor cells. Mol Cancer Ther. 2007;6:3208\u201318.","journal-title":"Mol Cancer Ther"},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s001090050142","volume":"75","author":"Q Xu","year":"1997","unstructured":"Xu Q, Wilkinson DG. Eph-related receptors and their ligands: mediators of contact dependent cell interactions. J Mol Med. 1997;75:576\u201386.","journal-title":"J Mol Med"},{"key":"2100_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrm856","volume":"3","author":"K Kullander","year":"2002","unstructured":"Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol. 2002;3:475\u201386.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2100_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrm1662","volume":"6","author":"EB Pasquale","year":"2005","unstructured":"Pasquale EB. Eph receptor signaling casts a wide net on cell behavior. Nat Rev Mol Cell Biol. 2005;6:462\u201375.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2100_CR18","doi-asserted-by":"publisher","first-page":"10815","DOI":"10.1158\/0008-5472.CAN-06-1408","volume":"66","author":"F Liu","year":"2006","unstructured":"Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 2006;66:10815\u201323.","journal-title":"Cancer Res"},{"key":"2100_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000103010","volume":"28","author":"X Li","year":"2007","unstructured":"Li X, Wang Y, Wang Y, Zhen H, Yang H, Fei Z, Zhang J, Liu W, Wang Y, Zhang X. Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis. Tumour Biol. 2007;28:165\u201372.","journal-title":"Tumour Biol"},{"key":"2100_CR20","first-page":"151","volume":"19","author":"LF Wang","year":"2008","unstructured":"Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep. 2008;19:151\u20136.","journal-title":"Oncol Rep"},{"issue":"1","key":"2100_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1479-5876-2-40","volume":"2","author":"M Hatano","year":"2004","unstructured":"Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, et al. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004;2(1):40. https:\/\/doi.org\/10.1186\/1479-5876-2-40.","journal-title":"J Transl Med"},{"issue":"1","key":"2100_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.semcdb.2011.10.019","volume":"23","author":"A Beauchamp","year":"2012","unstructured":"Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signaling. Semin Cell Dev Biol. 2012;23(1):109\u201315.","journal-title":"Semin Cell Dev Biol"},{"key":"2100_CR23","doi-asserted-by":"crossref","unstructured":"Debinski W, Wykosky J. Molecular targeting of IL-13R\u03b12 and EphA2 receptor in GBM. Chapter 35. In: CNS cancer: models, prognostic factors and targets. Ed. Ervin van Meir, Springer, New York, NY, 2009. p. 841\u2013858.","DOI":"10.1007\/978-1-60327-553-8_35"},{"issue":"8","key":"2100_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1593\/neo.05277","volume":"7","author":"M Hatano","year":"2005","unstructured":"Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005;7(8):717\u201322.","journal-title":"Neoplasia"},{"issue":"6","key":"2100_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ccr.2012.11.005","volume":"22","author":"E Binda","year":"2012","unstructured":"Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, et al. The epha2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 2012;22(6):765\u2013580.","journal-title":"Cancer Cell"},{"issue":"5","key":"2100_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/onc.2013.590","volume":"34","author":"H Miao","year":"2014","unstructured":"Miao H, Gale NW, Guo H, Qian J, Petty A, Kaspar J, et al. EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene. 2014;34(5):558\u201367.","journal-title":"Oncogene"},{"issue":"4","key":"2100_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1586\/14737175.8.4.515","volume":"8","author":"W Debinski","year":"2008","unstructured":"Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother. 2008;8(4):515\u20137.","journal-title":"Expert Rev Neurother"},{"issue":"37","key":"2100_CR28","doi-asserted-by":"publisher","first-page":"59860","DOI":"10.18632\/oncotarget.10978","volume":"7","author":"S Ferluga","year":"2016","unstructured":"Ferluga S, Tom\u00e9 CM, Herpai DM, D\u2019Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. 2016;7(37):59860\u201376.","journal-title":"Oncotarget"},{"issue":"2","key":"2100_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccr.2013.01.007","volume":"23","author":"BW Day","year":"2013","unstructured":"Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell. 2013;23(2):238\u201348.","journal-title":"Cancer Cell"},{"issue":"9","key":"2100_CR30","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1158\/0008-5472.CAN-03-3667","volume":"64","author":"M Nakada","year":"2004","unstructured":"Nakada M, Niska JA, Miyamori H, McDonough WS, Wu J, Sato H, Berens ME. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res. 2004;64(9):3179\u201385.","journal-title":"Cancer Res"},{"key":"2100_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.788587","volume":"10","author":"W Liu","year":"2022","unstructured":"Liu W, Yu C, Li J, Fang J. The roles of EphB2 in cancer. Front Cell Dev Biol. 2022;10: 788587.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"2100_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/neuonc\/noaa196","volume":"23","author":"JH Rossmeisl","year":"2020","unstructured":"Rossmeisl JH, Herpai D, Quigley M, Cecere TE, Robertson JL, D\u2019Agostino RB, et al. Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas. Neuro Oncol. 2020;23(3):422\u201334.","journal-title":"Neuro Oncol"},{"key":"2100_CR33","doi-asserted-by":"publisher","unstructured":"Sharma P, Sonawane P, Herpai D, Rossmeisl J, Tatter S, Debinski W. Multi-receptor targeting of glioblastoma. Neuro-Oncol Adv. 2020;2(1). https:\/\/doi.org\/10.1093\/noajnl\/vdaa107.","DOI":"10.1093\/noajnl\/vdaa107"},{"issue":"16","key":"2100_CR34","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.7150\/jca.18457","volume":"8","author":"X Dai","year":"2017","unstructured":"Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8(16):3131\u201341.","journal-title":"J Cancer"},{"key":"2100_CR35","doi-asserted-by":"crossref","unstructured":"Nakayama S, Torikoshi Y, Takahashi T. et al. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. Breast Cancer Res. 2009;11:R12.","DOI":"10.1186\/bcr2231"},{"key":"2100_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063254","volume":"25","author":"C Almeida-Ferreira","year":"2024","unstructured":"Almeida-Ferreira C, Marto Carmo C, Almeida-Ferreira J, Frutuoso C, Carvalho MJ, Botelho MF, Laranjo M. Efficacy of cold atmospheric plasma vs. chemotherapy in triple-negative breast cancer: a systematic review. Int J Mol Sci. 2024;25: 3254.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2100_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077719","volume":"8","author":"W Debinski","year":"2013","unstructured":"Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS ONE. 2013;8(10): e77719.","journal-title":"PLoS ONE"},{"issue":"2","key":"2100_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209.","journal-title":"Breast Cancer Res"},{"issue":"Pt 18","key":"2100_CR39","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1242\/jcs.00735","volume":"116","author":"C Prigent","year":"2003","unstructured":"Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci. 2003;116(Pt 18):3677\u201385.","journal-title":"J Cell Sci"},{"issue":"45","key":"2100_CR40","doi-asserted-by":"publisher","first-page":"30433","DOI":"10.1074\/jbc.R800035200","volume":"283","author":"C L\u00f3pez-Ot\u00edn","year":"2008","unstructured":"L\u00f3pez-Ot\u00edn C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem. 2008;283(45):30433\u20137.","journal-title":"J Biol Chem"},{"issue":"2","key":"2100_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.canlet.2011.03.017","volume":"307","author":"M Lopus","year":"2011","unstructured":"Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011;307(2):113\u20138.","journal-title":"Cancer Lett"},{"issue":"10","key":"2100_CR42","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","volume":"31","author":"F Montemurro","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350\u20138.","journal-title":"Ann Oncol"},{"key":"2100_CR43","first-page":"117","volume":"64","author":"A Mintz","year":"2003","unstructured":"Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha-2-expressing glioma. J Neuro-Oncol. 2003;64:117\u201323.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"2100_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ph13040077","volume":"13","author":"P Sharma","year":"2020","unstructured":"Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug conjugates for targeting Eph receptors in glioblastoma. Pharmaceuticals (Basel). 2020;13(4): 77.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"2100_CR45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173(4):879\u201393.","journal-title":"Cell"},{"key":"2100_CR46","doi-asserted-by":"crossref","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl, Mamounas EP, Untch M, Wolmark N, +22, for the KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u2013628.","DOI":"10.1056\/NEJMoa1814017"},{"issue":"2","key":"2100_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","volume":"1","author":"S Simon","year":"2020","unstructured":"Simon S, Riddell SR. Dual targeting with CAR T cells to limit antigen escape in myeloma. Blood Cancer Discov. 2020;1(2):130\u20133.","journal-title":"Blood Cancer Discov"},{"key":"2100_CR48","doi-asserted-by":"crossref","unstructured":"Mishra A, Maiti R, Mohan, Gupta P. Antigen loss following CAR-T cell therapy: mechanisms, implications, and potential solutions. Eur J Haemat. 2024;112(2):211\u2013222.","DOI":"10.1111\/ejh.14101"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02100-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02100-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:03:17Z","timestamp":1761573797000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02100-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02100-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No part of the manuscript is under consideration, in press, published, or reported in a scientific journal in the form of manuscript. All authors read and approved the manuscript. All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Waldemar Debinski is a co-inventor on several patent applications related to the subject of this manuscript; several of them have been licensed to WPD Pharmaceuticals. Kaitlin N. Fink, Ryan T. Mott, and Kounosuke Watabe have nothing to disclose.\u00a0John Rossmeisl is a co-inventor on a patent application covering QUAD-DM1 cytotoxin. Alexandra Thomas reports stock ownership: Johnson & Johnson, Gilead Sciences, Bristol Myers Squibb, Pfizer; consulting or advisory role: Genentech, AstraZeneca; Research Funding: Sanofi, Merck (to the institution); royalties. Denise Herpai is a co-inventor on several patent applications related to the subject of this manuscript; several of them have been licensed to WPD Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}